Results 131 to 140 of about 24,414 (214)

Proprotein convertase subtilisin/ kexin type 9 levels and arterial function

Atherosclerosis, 2018
Koutagiar, I., Vlachopoulos, C., Terentes-Printzios, D., Skoumas, J., Skliros, N., Rigatou, A., Ioakeimidis, N., Pantou, S., Georgakopoulos, C., Miliou, A., Tousoulis, D.   +10 more
openaire   +2 more sources

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study. [PDF]

J Int Med Res
Wang Y, Liu X, Huang S.
europepmc   +1 more source

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Adv Ther
Masson W, Lobo M, Giunta G, Barbagelata L, Nogueira JP.   +4 more
europepmc   +1 more source

Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys [PDF]

Current Opinion in Lipidology, 2019
Ya, Wang, Murong, Ma, Jian-An, Wang, Alan, Daugherty, Hong S, Lu   +4 more
openaire   +2 more sources

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia

Chinese Medical Journal, 2022
Yanren Peng, Danxia Guo, Sijie Jiang, Hua Zheng, Lishao Guo   +4 more
doaj   +1 more source

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. [PDF]

Interdiscip Cardiovasc Thorac Surg
Yokoyama Y, Higashino H, Fujieda H, Abe M.   +3 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]

Angiology, 2013
openaire   +5 more sources

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source